health – Page 6

NIH budget cuts affect research funding beyond US borders

budget cuts, health, NIH, Science, syndication, Trump / Kelly Newman / June 30, 2025

European leaders say they will fill the funding void. Is that realistic?

Credit: E+ via Getty Images

Rory de Vries, an associate professor of virology in the Netherlands, was lifting weights at the gym when he noticed a WhatsApp message from his research partners at Columbia University, telling him his research funding had been cancelled. The next day he received the official email: “Hi Rory, Columbia has received a termination notice for this contract, including all subcontracts,” it stated. “Unfortunately, we must advise you to immediately stop work and cease incurring charges on this subcontract.”

De Vries was disappointed, though not surprised—his team knew this might happen under the new Trump administration. His projects focused on immune responses and a new antiviral treatment for respiratory viruses like Covid-19. Animals had responded well in pre-clinical trials, and he was about to explore the next steps for applications in humans. But the news, which he received in March, left him with a cascade of questions: What would happen to the doctoral student he had just hired for his project, a top candidate plucked from a pool of some 300 aspiring scientists? How would his team comply with local Dutch law, which, unlike the US, forbids terminating a contract without cause or notice? And what did the future hold for his projects, two of which contained promising data for treating Covid-19 and other respiratory illnesses in humans?

It was all up in the air, leaving de Vries, who works at the Erasmus Medical Center in Rotterdam and whose research has appeared in top-tier publications scrambling for last-minute funding from the Dutch government or the European Union.

Of the 20 members in his group, he will soon run out of money to pay the salaries for four. As of June, he

estimated that his team has enough to keep going for about six months in its current form if it draws money from other funding sources.

But that still leaves funding uncertain in the long-term: “So, yeah, that’s a little bit of an emergency solution,” he said.

Cuts to science funding in the US have devastated American institutions, hitting cancer research and other vital fields, but they also affect a raft of international collaborations and scientists based abroad. In Canada, Australia, South Africa and elsewhere, projects receiving funds from the National Institutes of Health have been terminated or stalled due to recent budget cuts.

Researchers in Europe and the US have long collaborated to tackle tough scientific questions. Certain fields, like rare diseases, particularly benefit from international collaboration because it widens the pool of patients available to study. European leaders have said that they will step into the gap created by Trump’s NIH cuts to make Europe a magnet for science—and they have launched a special initiative to attract US scientists. But some researchers doubt that Europe alone can truly fill the void.

In many European countries, scientist salaries are modest and research funding has lagged behind inflation in recent years. In a May press release, a French scientists’ union described current pay as “scandalously low” and said research funding in France and Europe as a whole lags behind the US, South Korea, China, Taiwan, and Japan. Europe and its member states would need to increase research funding by up to 150 billion euros (roughly USD $173 billion) per year to properly support science, said Boris Gralak, general secretary of the French union, in an interview with Undark.

The shifts are not just about money, but the pattern of how international research unfolds, said Stefan Pfister, a pediatric cancer specialist in Germany who has also received NIH funds. The result, he said, is “this kind of capping and compromising well-established collaborations.”

Funding beyond US borders

For decades, international researchers have received a small slice of the National Institutes of Health budget. In 2024, out of an overall budget of $48 billion, the NIH dispensed $69 million to 125 projects across the European continent and $262 million in funding worldwide, according to the NIH award database.

The US and Europe “have collaborated in science for, you know, centuries at this point,” said Cole Donovan, associate director of science and technology ecosystem development at the Federation of American Scientists, noting that the relationship was formalized in 1997 in an agreement highlighting the two regions’ common interests.

And it has overall been beneficial, said Donovan, who worked in the State Department for a decade to help facilitate such collaborations. In some cases, European nations simply have capabilities that do not exist in the US, like the Czech Republic and Romania, he said, which have some of the most sophisticated laser facilities in the world.

“If you’re a researcher and you want to use those facilities,” he added, “you have to have a relationship with people in those countries.”

Certain fields, like rare diseases, particularly benefit from international collaboration because it widens the pool of patients available to study.

The shared nature of research is driven by personal connections and scientific interest, Donovan said: “The relationship in science and technology is organic.”

But with the recent cuts to NIH funding, the fate of those research projects—particularly on the health effects of climate change, transgender health, and Covid-19—has been thrown into question. On May 1, the NIH said it would not reissue foreign subawards, which fund researchers outside the US who work with American collaborators—or agree to US researchers asking to add a foreign colleague to a project. The funding structure lacked transparency and could harm national security, the NIH stated, though it noted that it would not “retroactively revise ongoing awards to remove foreign subawards at this time.” (The NIH would continue to support direct foreign awards, according to the statement.)

The cuts have hit European researchers like de Vries, whose institution, Erasmus MC, was a sub-awardee on three Columbia University grants to support his work. Two projects on Covid-19 transmission and treatment have ended abruptly, while another, on a potential treatment for measles, has been frozen, awaiting review at the end of May, though by late June he still had no news and said he assumed it would not be renewed. “We’re trying to scrape together some money to do some two or three last experiments, so we at least can publish the work and that it’s in literature and anyone else can pick it up,” he said. “But yeah, the work has stopped.”

His Ph.D. students must now shift the focus of their theses; for some, that means pivoting after nearly three years of study.

De Vries’ team has applied for funds from the Dutch government, as well as sought industry funding, for a new project evaluating a vaccine for RSV—something he wouldn’t have done otherwise, he said, since industry funding can limit research questions. “Companies might not be interested in in-depth immunological questions, or a side-by-side comparison of their vaccine with the direct competition,” he wrote in an email.

International scientists who have received direct awards have so far been unaffected, but say they are still nervous about potential further cuts. Pfister, for example, is now leading a five-year project to develop treatments for childhood tumors; with the majority of funding coming from NIH and Cancer Research U.K., a British-based cancer charity, “not knowing what the solution will look like next year,” he said, “generates uncertainties.”

The jointly funded $25 million project—which scientists from nine institutions across five countries including the US are collaborating on—explores treatments for seven childhood cancers and offers a rare opportunity to make progress in tackling tumors in children, Pfister added, as treatments have lagged in the field due to the small market and the high costs of development. Tumors in children differ from those in adults and, until recently, were harder to target, said Pfister. But new discoveries have allowed researchers to target cancer more specifically in children, and global cooperation is central to that progress.

The US groups, which specialize in drug chemistry, develop lead compounds for potential drugs. Pfister’s team then carries out experiments on toxicity and effectiveness. The researchers hope to bring at least one treatment, into early-phase clinical trials.

Funding from NIH is confirmed for this financial year. Beyond that, the researchers are staying hopeful, Pfister said.

“It’s such an important opportunity for all of us to work together,” said Pfister, “that we don’t want to think about worst-case scenarios.”

Pfister told Undark that his team in Heidelberg, Germany, has assembled the world´s biggest store of pediatric cancer models; no similar stock currently exists in the US The work of the researchers is complementary, he stressed: “If significant parts would drop out, you cannot run the project anymore.”

Rare diseases benefit from international projects, he added. In these fields, “We don’t have the patient numbers, we don’t have the critical mass,” in one country alone, he said. In his field, researchers conduct early clinical trials in patients on both sides of the Atlantic. “That’s just not because we are crazy, but just because this the only way to physically conduct them.”

The US has spearheaded much drug development, he noted. “Obviously the US has been the powerhouse for biomedical research for the last 50 years, so it’s not surprising that some of the best people and the best groups are sitting there,” he said. A smaller US presence in the field would reduce the critical mass of people and resources available, which would be a disaster for patients, he said. “Any dreams of this all moving to Europe are illusions in my mind.”

While Europe has said it will step in to fill the gap, the amounts discussed were not enough, Gralak said. The amount of money available in Europe “is a very different order of magnitude,” Pfister said. It also won’t help their colleagues in the US, who European researchers need to thrive in order to maintain necessary collaborations, he said. “In the US, we are talking about dozens of billions of dollars less in research, and this cannot be compensated by any means, by the EU or any other funder.” Meanwhile, the French scientists’ union said the country has failed to meet funding promises made as long ago as 2010.

And although Europe receives a sliver of NIH funds, these cuts could have a real impact on public health. De Vries said that his measles treatment was at such an early stage that its potential benefits remained unproven, but if effective it could have been the only treatment of its kind at a time when cases are rising.

And he said the stalling of both his work and other research on Covid-19 leaves the world less prepared for a future pandemic. The antiviral drug he has developed had positive results in ferrets but needs further refinement to work in humans. If the drugs were available for people, “that would be great,” he said. “Then we could actually work on interrupting a pandemic early.”

New opportunities for Europe

The shift in US direction offers an opportunity for the EU, said Mike Galsworthy, a British scientist who campaigned to unite British and EU science in the wake of Brexit. The US will no longer be the default for ambitious researchers from across the world, he said: “It’s not just US scientists going to Canada and Europe. There’s also going to be the huge brain diversion.” he said. “If you are not a native English speaker and not White, you might be extra nervous about going to the States for work there right now,” he added.

And in recent weeks, European governments have courted fleeing scientists. In April, France launched a platform called Choose France for Science, which allows institutions to request funding for international researchers, and highlights an interest in health, climate science, and artificial intelligence, among other research areas Weeks later, the European Union announced a new program called Choose Europe for Science, aiming to make Europe a “magnet for researchers.” It includes a 500 million Euro (roughly USD $578 million) funding package for 2025-2027, new seven-year “super grants,” to attract the best researchers, and top-up funds that would help scientists from outside Europe settle into their new institution of choice.

The initial funding comes from money already allocated to Horizon Europe—the EU’s central research and innovation funding program. But some researchers are skeptical. The French union leader, Gralak, who is also a researcher in mathematical physics, described the programs as PR initiatives. He criticized European leaders for taking advantage of the problems in US science to attract talent to Europe, and said leaders should support science in Europe through proper and sufficient investment. The programs are “derisory and unrealistic,” he said.

“It’s not just US scientists going to Canada and Europe. There’s also going to be the huge brain diversion.”

Others agreed that Europe’s investment in science is inadequate. Bringing scientists to Europe would be “great for science and the talent, but that also means that will come from a line where there’s normally funding for European researchers,” said de Vries, the researcher from Rotterdam. As Mathilde Richard, a colleague of de Vries who works on viruses and has five active NIH grants, told Undark: “Why did I start to apply to NIH funds? And still, the most straightforward answer is that there isn’t enough in Europe.”

In the Netherlands, a rightwing government has said it will cut science funding by a billion euros over the next five years. And while the flagship program Horizon Europe encourages large-scale projects spanning multiple countries, scientists spend years putting together the major cross-country collaborations the system requires. Meanwhile, European Research Council grants are “extremely competitive and limited,” de Vries said.

Richard’s NIH grants pay for 65 percent of her salary and for 80 percent of her team, and she believes she’s the most dependent on US funds of anyone in her department at Erasmus Medical Center in Rotterdam. She applied because the NIH funding seemed more sustainable than local money, she said. In Europe, too often funding is short-term and has a time-consuming administrative burden, she said, which hinders researchers from developing long-term plans. “We have to battle so much to just do our work and find funds to just do our basic work,” she said. “I think we need to advocate for a better and more sustainable way of funding research.”

Scientists, too, are worried about what US cuts mean for global science, beyond the short-term. Paltry science funding could discourage a generation of talented people from entering the field, Pfister suggested: “In the end, the resources are not only monetary, but also the brain resources are reduced.”

Let’s not talk about it

A few months ago, Pfister attended a summit in Boston for Cancer Grand Challenges, a research initiative co-funded by the NIH’s National Cancer Institute and Cancer Research U.K. Nobody from the NIH came because they had no funding to travel. “So we are all sitting in Boston, and they are sitting like 200 miles away,” he said.

More concerning was the fact that those present seemed afraid to discuss why the NIH staff were absent, he said. “It was us Europeans to basically, kind of break the ice to, you know, at least talk about it.”

Pfister said that some European researchers are now hesitant about embarking on US collaborations, even if there is funding available. And some German scientists are taking steps to ensure that they are protected if a similar budget crackdown occurred in Germany, he said—devising independent review processes, separating research policy from funding, and developing funding models less dependent on government-only sources, he said. “I think the most scary part is that you know, this all happened in three months.”

Despite the worry and uncertainty, de Vries offered a hopeful view of the future. “We will not be defeated by NIH cuts,” he said. “I feel confident that Europe will organize itself.”

This article was originally published on Undark. Read the original article.

NIH budget cuts affect research funding beyond US borders Read More »

SCOTUS upholds part of ACA that makes preventive care fully covered

ACA, health, preventive services, US Supreme Court, USPSTF / DJ Henderson / June 28, 2025

The USPSTF is made up of 16 medical experts who carefully review scientific data and run models to assess what preventive health interventions are best, using a framework of recommendation gradings from A to F. Any recommendations graded A or B by the task force are required by the ACA to be covered by health plans at no cost to patients.

The US health department argued that the task force members are, in fact, appointed, and under control of the health secretary, a role currently filled by anti-vaccine advocate Robert F. Kennedy Jr.

Two lower courts in Texas sided with the Christian group, saying that the government violated the appointments clause.

But today, in a 6–3 ruling, the Supreme Court disagreed. Chief Justice John Roberts and Justices Amy Coney Barrett, Brett Kavanaugh, Elena Kagan, Ketanji Brown Jackson, and Sonia Sotomayor made up the majority.

Writing on their behalf, Kavanaugh explained: “Task Force members are supervised and directed by the Secretary, who in turn answers to the President, preserving the chain of command in Article II.”

While the ruling means that coverage of preventive health care is no longer under threat, the ruling clarifies that the health secretary has direct authority over the USPSTF. The clarification raises concern that the current secretary, Kennedy, could remove task force members and/or undo recommendations to suit his personal ideology, as he is now doing with the vaccine advisory board at the Centers for Disease Control and Prevention.

SCOTUS upholds part of ACA that makes preventive care fully covered Read More »

Man eats dubious street food—ends up blowing apart his GI tract

Boerhaave syndrome, esophagus, food, health, medical case report, New England Journal of Medicine, vomiting / Shannon Garcia / June 28, 2025

Bilious blowout

Doctors noted that his breath was fast and shallow, with crackling in his neck. But breathing sounds from the base of his right lung were quiet. A computed tomography (CT) scan revealed the problems. There was air in his chest space and into his neck. Fluid was also building up around his lungs, and his right lung was collapsing. The scan also showed a perforation in the esophagus.

The doctors inserted a chest tube to remove the fluid, which did not include gastric contents, suggesting the fluid build-up was from chest inflammation.

The doctors then did an additional X-ray exam of the esophagus using a water-soluble contrast agent. This clearly revealed a large gash in the man’s esophagus resulting from the robust eruption. The imaging also showed the contrast agent leaking out into the man’s chest.

The doctors quickly sent the man into emergency surgery to repair his esophagus. He spent the next 35 days in the hospital recovering. When he was discharged, he still had a feeding tube that passed through his nose and into his small intestine. It took an additional three months for the perforation to completely heal, at which point doctors could finally remove the feeding tube.

It’s not entirely clear what causes Boerhaave syndrome. Researchers hypothesize that it occurs from a loss of neuromuscular coordination, which, in particular, causes the upper sphincter in the esophagus—the cricopharyngeus—to fail to relax at the onset of vomiting. The rapid rise of internal pressure overwhelms the esophagus, typically causing a lengthwise tear in the lower third of the tube, which is the weakest portion. On average, tears can be up to 8 centimeters (about 3 inches) long.

Though researchers expect that cases are underreported, the estimated incidence based on reports is about three cases per million people globally each year.

Man eats dubious street food—ends up blowing apart his GI tract Read More »

RFK Jr.’s CDC panel ditches some flu shots based on anti-vaccine junk data

ACIP, anti-vaccine, CDC, health / Shannon Garcia / June 27, 2025

Flu shots with thimerosal abandoned, despite decades of data showing they’re safe.

Dr. Martin Kulldorff, chair of the Advisory Committee on Immunization Practices, during the first meeting of the CDC’s Advisory Committee On Immunization Practices on June 25, 2025. Credit: Getty | Bloomberg

The vaccine panel hand-selected by health secretary and anti-vaccine advocate Robert F. Kennedy Jr. on Thursday voted overwhelmingly to drop federal recommendations for seasonal flu shots that contain the ethyl-mercury containing preservative thimerosal. The panel did so after hearing a misleading and cherry-picked presentation from an anti-vaccine activist.

There is extensive data from the last quarter century proving that the antiseptic preservative is safe, with no harms identified beyond slight soreness at the injection site, but none of that data was presented during today’s meeting.

The significance of the vote is unclear for now. The vast majority of seasonal influenza vaccines currently used in the US—about 96 percent of flu shots in 2024–2025—do not contain thimerosal. The preservative is only included in multi-dose vials of seasonal flu vaccines, where it prevents the growth of bacteria and fungi potentially introduced as doses are withdrawn.

However, thimerosal is more common elsewhere in the world for various multi-dose vaccine vials, which are cheaper than the single-dose vials more commonly used in the US. If other countries follow the US’s lead and abandon thimerosal, it could increase the cost of vaccines in other countries and, in turn, lead to fewer vaccinations.

Broken process

However, it remains unclear what impact today’s vote will have—both in the US and abroad. Normally, before voting on any significant changes to vaccine recommendations from the Centers for Disease Control and Prevention, the committee that met today—the CDC’s Advisory Committee on Immunization Practices (ACIP)— would go through an exhaustive process. That includes thoroughly reviewing and discussing the extensive safety and efficacy data of the vaccines, the balance of their benefits and harms, equity considerations, and the feasibility and resource implications of their removal.

But, instead, the committee heard a single presentation given by anti-vaccine activist, Lyn Redwood, who was once the president of the anti-vaccine organization founded by Kennedy, Children’s Health Defense.

Thimerosal has long been a target of anti-vaccine activists like Redwood, who hold fast to the false and thoroughly debunked claim that vaccines—particularly thimerosal-containing vaccines—cause autism and neurological disorders. Her presentation today was a smorgasbord of anti-vaccine talking points against thimerosal, drawing on old and fringe studies she claimed prove that thimerosal is an ineffective preservative, kills cells in petri dishes, and can be found in the brains of baby monkeys after it has been injected into them. The presentation did not appear to have gone through any vetting by the CDC, and an earlier version contained a reference to a study that does not exist.

Yesterday, CBS News reported that the Centers for Disease Control and Prevention is hiring Redwood to oversee vaccine safety. In response, Sen. Patty Murray (D-Wash.) called Redwood an “extremist,” and urged the White House to immediately reverse the decision. “We cannot allow a few truly deranged individuals to distort the plain truth and facts around vaccines so badly,” Murray said in a statement.

CDC scientists censored

Prior to the meeting, CDC scientists posted a background briefing document on thimerosal. It contained summaries of around two dozen studies that all support the safety of thimerosal and/or find no association with autism or neurological disorders. It also explained how in 1999, health experts and agencies made plans to remove thimerosal from childhood vaccines out of an abundance of caution for concern that it was adding to cumulative exposures that could hypothetically become toxic—at high doses, thimerosal can be dangerous. By 2001, it was removed from every childhood vaccine in the US and remains so to this day. But, since then, studies have found thimerosal to be perfectly safe in vaccines. All the studies listed by the CDC in support of thimerosal were published after 2001.

The document also contained a list of nearly two dozen studies claiming to find a link to autism, but where described by the CDC as having “significant methodological limitations.” The Institute of Medicine also called them “uninterpretable, and therefore, noncontributory with respect to causality.” Every single one of the studies was authored by the anti-vaccine father and son duo Mark and David Geier.

In March, it came to light that Kennedy had hired David Geier to the US health department to continue trying to prove a link between autism and vaccines. He is now working on the issue.

The CDC’s thimerosal document was removed from the ACIP’s meeting documents prior to the meeting. Robert Malone, one of the new ACIP members who holds anti-vaccine views, said during the meeting that it was taken down because it “was not authorized by the Office of the Secretary [Kennedy].” You can read it here.

Lone voice

In the meeting today, Kennedy’s hand-selected ACIP members did not ask Redwood any questions about the data or arguments she made against thimerosal. Nearly all of them readily accepted that thimerosal should be removed entirely. The only person to push back was Cody Meissner, a pediatric professor at Dartmouth’s Geisel School of Medicine who has served on ACIP in the past—arguably the most qualified and reasonable member of the new lineup.

“I’m not quite sure how to respond to this presentation,” he said after Redwood finished her slides. “This is an old issue that has been addressed in the past. … I guess one of the most important [things] to remember is that thimerosal is metabolized into ethylmercury and thiosalicylate. It’s not metabolized into methylmercury, which is in fish and shellfish. Ethylmercury is excreted much more quickly from the body. It is not associated with the high neurotoxicity that methylmercury is,” he explained.

Meissner scoffed at the committee even spending time on it. “So, of all the issues that I think we, ACIP, needs to focus on, this is not a big issue. … no study has ever indicated any harm from thimerosal. It’s been used in vaccines … since before World War II.

But he did express concern that it could be removed from the vaccine used globally.

“The recommendations the ACIP makes are followed among many countries around the world,” he said. “And removing thimerosal from all vaccines that are used in other countries, for example, is going to reduce access to these vaccines.”

Anti-vaccine agenda

In the end, the seven-member panel voted in favor of recommending only those seasonal flu vaccines that did not contain thimerosal. There were three separate votes for this, making this recommendation for children, pregnant women, and all adults each, but all with the same outcome: five ‘yes’ votes, one ‘no’ vote (Meissner), and one abstention from anti-vaccine activist and nurse Vicky Pebsworth. After the vote, Pebsworth clarified that she did not support the use of thimerosal in vaccines, but had a quibble with how the voting questions were written.

Prior to the vote, ACIP Chair Martin Kulldorff gave a brief presentation on the MMRV vaccine (measles, mumps, rubella, and varicella/chickenpox). He previewed a proposed recommendation to vote on in a future meeting that would remove the CDC’s recommendation for that vaccine as well.

Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes.

RFK Jr.’s CDC panel ditches some flu shots based on anti-vaccine junk data Read More »

All childhood vaccines in question after first meeting of RFK Jr.’s vaccine panel

ACIP, anti-vaccine, CDC, COVID-19, health, influenza, measles, Robert F Kenned Jr., vaccination / Shannon Garcia / June 26, 2025

A federal vaccine panel entirely hand-selected by health secretary and anti-vaccine activist Robert F. Kennedy Jr. gathered for its first meeting Wednesday—and immediately announced that it would re-evaluate the entire childhood vaccination schedule, as well as the one for adults.

The meeting overall was packed with anti-vaccine talking points and arguments from the new panel members, confirming public health experts’ fears that the once-revered panel is now critically corrupted and that Kennedy’s controversial picks will only work to fulfill his long-standing anti-vaccine agenda.

Controversial committee

An hour before the meeting began, the American Academy of Pediatrics came out swinging against the new panel, saying that the panel’s work is “no longer a credible process.” The organization shunned the meeting, refusing to send a liaison to the panel’s meeting, which it has done for decades.

“We won’t lend our name or our expertise to a system that is being politicized at the expense of children’s health,” AAP President Susan Kressly said in a video posted on social media.

The panel in question, the Advisory Committee on Immunization Practices (ACIP), has for more than 60 years provided rigorous public scientific review, discussion, and trusted recommendations to the Centers for Disease Control and Prevention on how vaccines should be used in the US after they’ve earned approval from the Food and Drug Administration. The CDC typically adopts ACIP’s recommendations, and once that happens, insurance providers are required to cover the cost of the recommended shots.

The system is highly regarded globally. But, on June 9, Kennedy unilaterally and summarily fired all 17 esteemed ACIP members and, two days later, replaced them with eight new people. Some have clear anti-vaccine views, others have controversial and contrarian public health views, and several have little to no expertise in the fields relevant to vaccines.

Last night, it came to light that one of the eight new appointees—Michael Ross, an obstetrics and gynecology physician—had withdrawn from the committee during a financial holdings review that ACIP members are required to complete before beginning work on the panel.

All childhood vaccines in question after first meeting of RFK Jr.’s vaccine panel Read More »

CDC’s once-revered vaccine panel now a “farce”—calls grow to scrap meeting

ACIP, anti-vaccine, CDC, flu vaccine, health, measles, robert f kennedy jr / 9u50fv / June 24, 2025

“The meeting should be delayed until the panel is fully staffed with more robust and balanced representation—as required by law—including those with more direct relevant expertise,” Cassidy wrote.

“Corrupted”

Vaccine and infectious disease expert Peter Hotez, a dean at Baylor College of Medicine, responded to Cassidy, adding, “Honestly in its current form, the ACIP is mostly devoid of any meaningful expertise in vaccines or infectious diseases. It is organized to pursue a pseudoscience agenda. It’s a waste of taxpayer dollars and should be dissolved. Perhaps down the line it could be resurrected.”

One of the CDC’s leading vaccine experts, Fiona Havers—who recently resigned from the agency in protest—went further to say the CDC’s vaccine processes have been “corrupted in a way that I haven’t seen before.”

“If it isn’t stopped, and some of this isn’t reversed, like, immediately, a lot of Americans are going to die as a result of vaccine-preventable diseases,” she told The New York Times.

Meanwhile, Kennedy’s anti-vaccine agenda appears to be moving forward undeterred. On Tuesday, the CDC released the final agenda for tomorrow ‘s ACIP meeting. Kennedy had already altered the agenda to add discussions of two long-standing vaccines: certain flu vaccines that use the mercury-based preservative thimerosal and certain measles vaccines. There is no controversy over these vaccines among experts, but they have long been the target of misinformation and fearmongering by anti-vaccine advocates, including Kennedy.

According to the final ACIP agenda, the meeting will also now include a presentation and recommendations on flu vaccines from Lyn Redwood. She is a nurse with no expertise in vaccinations, infectious diseases, or any other relevant field for the ACIP. Rather, she was the president of Kennedy’s rabid anti-vaccine organization Children’s Health Defense and promotes the debunked falsehood that thimerosal-containing vaccines cause autism.

CDC’s once-revered vaccine panel now a “farce”—calls grow to scrap meeting Read More »

Man’s health crashes after getting donated kidney—it was riddled with worms

health, infection, Massachusetts General Hospital, NEJM, parasitic worms, strongyloides, Strongyloides stercoralis / Mike M. / June 21, 2025

About two months after receiving a donated kidney, a 61-year-old man ended up back in the hospital. He was tired, nauseous, and vomiting. He was also excessively thirsty and producing too much urine. Over the next 10 days, things only got worse. The oxygen levels in his blood began to fall. His lungs filled with fluid. He kept vomiting. He couldn’t eat. Doctors inserted a feeding tube. His oxygen levels and blood pressure kept falling. He was admitted to the intensive care unit and put on mechanical ventilation. Still, things kept getting worse.

At that point, he was transferred to the ICU of Massachusetts General Hospital, where he had received the transplant. He was in acute respiratory failure and shock.

In a case report in this week’s issue of the New England Journal of Medicine, doctors at Mass General explained how they determined what was wrong with the man. Their first steps were collecting more information about the man’s symptoms from his wife, reviewing his family medical history, and contacting the regional organ-procurement organization that provided the kidney.

Process of elimination

The man’s condition and laboratory tests suggested he had some sort of infection. But as a transplant recipient who was on a variety of immunosuppressive drugs, the list of infectious possibilities was “extensive.”

Dr. Camille Kotton, Clinical Director of the hospital’s Transplant and Immunocompromised Host Infectious Diseases division, laid out her thinking. She started with a process of elimination. As an immunosuppressed transplant patient, he was also on several medications to proactively prevent infections. These would rule out herpesviruses and cytomegalovirus. He was also on a combination of antibiotics that would rule out many bacterial infections, as well as the fungal infection Pneumocystis jirovecii that strikes the immunocompromised and the protozoan parasite Toxoplasma gondii.

One feature stood out: The man had developed elevated levels of eosinophils, white blood cells that can increase for various reasons—including parasitic infections. The man also had a reddish-purple rash over his abdomen. Coupled with the severity of his illness, Kotton suspected a widespread parasitic infection.

The man’s history was notable for contact with domestic cats and dogs—including a cat scratch in the time between having the transplant and falling critically ill. But common bacterial infections linked to cat scratches could be ruled out. And other parasitic infections that might come from domestic animals in the US, such as toxocariasis, don’t typically lead to such critical illnesses.

Man’s health crashes after getting donated kidney—it was riddled with worms Read More »

After RFK Jr. overhauls CDC panel, measles and flu vaccines are up for debate

ACIP, ant-vaccine, CDC, flu, health, measles, mmrv, robert f kennedy jr, thimerosal / 9u50fv / June 19, 2025

With ardent anti-vaccine activist Robert F. Kennedy Jr. in the country’s top health position, use of a long-approved vaccine against measles, mumps, rubella, and varicella/chickenpox (MMRV) as well as flu shots that include the preservative thimerosal will now be reevaluated, putting their future availability and use in question. The development seemingly continues to vindicate health experts’ worst fears that, as health secretary, Kennedy would attack and dismantle the federal government’s scientifically rigorous, evidence-based vaccine recommendations.

Discussions of the two types of vaccines now appear on the agenda of a meeting for the Centers for Disease Control and Prevention’s Advisory Committee for Immunization Practices (ACIP) scheduled for two days next week (June 25 and 26).

ACIP’s overhaul

On June 9, Kennedy summarily fired all 17 members of ACIP, who were rigorously vetted—esteemed scientists and clinicians in the fields of immunology, epidemiology, pediatrics, obstetrics, internal and family medicine, geriatrics, infectious diseases, and public health. Two days later, Kennedy installed eight new members, many with dubious qualifications and several known to hold anti-vaccine views.

Before ACIP was upended by Kennedy, the committee planned to meet for three days, from June 25 to 27, to discuss a wide array of vaccines, including those against anthrax, chikungunya, COVID-19, cytomegalovirus (CMV), Human papillomavirus (HPV), influenza, Lyme disease, meningococcal disease, pneumococcal disease, and respiratory syncytial virus (RSV). The committee was going to vote on recommendations for the use of COVID-19 vaccines, the HPV vaccine, influenza vaccines, the meningococcal vaccine, RSV vaccines for adults, and the RSV vaccine for maternal and pediatric populations.

In the new agenda, discussion on vaccines against CMV, HPV, Lyme disease, meningococcal disease, and pneumococcal disease has been dropped. So have votes for COVID-19 vaccines, HPV, meningococcal vaccines, and RSV vaccines for adults. Instead, the new ACIP will now discuss MMRV and influenza vaccines containing thimerosal. It will only vote on two matters: RSV vaccines for children and pregnant people, and influenza vaccines, including thimerosal-containing flu vaccines.

After RFK Jr. overhauls CDC panel, measles and flu vaccines are up for debate Read More »

All 17 fired vaccine advisors unite to blast RFK Jr.’s “destabilizing decisions”

ACIP, anti-vaccine, CDC, COVID-19, fda, health, rfk jr, robert f kennedy jr, vaccines / DJ Henderson / June 18, 2025

The members highlighted their medical and scientific expertise, lengthy vetting, transparent processes, and evidence-based approach to helping set federal immunization programs, which affect insurance coverage. They also lamented the institutional knowledge lost by the removal of the entire committee and its executive secretary, as well as cuts to the CDC broadly. Together they “have left the US vaccine program critically weakened,” the experts write.

“In this age of government efficiency, the US public needs to know that the routine vaccination of approximately 117 million children from 1994–2023 likely prevented around 508 million lifetime cases of illness, 32 million hospitalizations, and 1,129,000 deaths, at a net savings of $540 billion in direct costs and $2.7 trillion in societal costs,” they write.

They also took direct aim at Kennedy, who unilaterally changed the COVID-19 vaccination policy, announcing the changes on social media. This “bypassed the standard, transparent, and evidence-based review process,” they write. “Such actions reflect a troubling disregard for the scientific integrity that has historically guided US immunization strategy.”

Since Kennedy has taken over the US health department, many other vaccine experts have been pushed out or left voluntarily. Peter Marks, the former top vaccine regulator at the Food and Drug Administration, was reportedly given the choice to resign or be fired. In his resignation letter, he wrote: “it has become clear that truth and transparency are not desired by the Secretary [Kennedy], but rather he wishes subservient confirmation of his misinformation and lies.”

All 17 fired vaccine advisors unite to blast RFK Jr.’s “destabilizing decisions” Read More »

New COVID variant swiftly gains ground in US; concern looms for summer wave

CDC, COVID-19, ECDC, Europe, health, NB.1.8.1, omicron, SARS-CoV-2, vaccines, variant, WHO / 9u50fv / June 17, 2025

While COVID-19 transmission remains low in the US, health experts are anxious about the potential for a big summer wave as two factors seem set for a collision course: a lull in infection activity that suggests protective responses have likely waned in the population, and a new SARS-CoV-2 variant with an infectious advantage over other variants.

The new variant is dubbed NB.1.8.1. Like all the other currently circulating variants, it’s a descendant of omicron. Specifically, NB.1.8.1 is derived from the recombinant variant XDV.1.5.1. Compared to the reigning omicron variants JN.1 and LP.8.1, the new variant has a few mutations that could help it bind to human cells more easily and evade some protective immune responses.

On May 23, the World Health Organization designated NB.1.8.1 a “variant under monitoring,” meaning that early signals indicate it has an advantage over other variants, but its impact on populations is not yet clear. In recent weeks, parts of Asia, including China, Hong Kong, Singapore, and Taiwan, have experienced increases in infections and hospitalizations linked to NB.1.8.1’s spread. Fortunately, the variant does not appear to cause more severe disease, and current vaccines are expected to remain effective against it.

Still, it appears to be swiftly gaining ground in the US, fueling worries that it could cause a surge here as well. In the latest tracking data from the Centers for Disease Control and Prevention, NB.1.8.1 is estimated to account for 37 percent of cases in the US. That’s up from 15 percent two weeks ago. NB.1.8.1 is now poised to overtake LP.8.1, which is estimated to make up 38 percent of cases.

It’s important to note that those estimates are based on limited data, so the CDC cautions that there are large possible ranges for the variants’ actual proportions. For NB.1.81, the potential percentage of cases ranges from 13 percent to 68 percent, while LP.8.1’s is 23 percent to 57 percent.

New COVID variant swiftly gains ground in US; concern looms for summer wave Read More »

After a series of tumors, woman’s odd-looking tongue explains everything

cowden syndrome, health, PTEN / 9u50fv / June 13, 2025

Breast cancer. Colon cancer. An enlarged thyroid gland. A family history of tumors and cancers as well. It wasn’t until the woman developed an annoying case of dry mouth that doctors put it all together. By then, she was in her 60s.

According to a new case study in JAMA Dermatology, the woman presented to a dermatology clinic in Spain after three months of oral unpleasantness. They noted the cancers in her medical history. When she opened wide, doctors immediately saw the problem: Her tongue was covered in little wart-like bumps that resembled a slippery, flesh-colored cobblestone path. (Image here.)

Such a cobblestone tongue is a telltale sign of a rare genetic condition called Cowden syndrome. It’s caused by inherited mutations that break a protein, called PTEN, leading to tumors and cancers.

PTEN, which stands for phosphatase and tensin homolog, generally helps keep cells from growing out of control. Specifically, PTEN deactivates a signaling lipid called PIP₃ (phosphatidylinositol 3,4,5-trisphosphate), and that deactivation blocks a signaling pathway (the PI3K/AKT/mTOR pathway) involved in regulating cell growth, survival, and migration. When PTEN is broken, PIP₃ activity ramps up, and tumors can grow unchecked.

Not-so-rare mutation

In Cowden syndrome, PTEN mutations lead to noncancerous tumors or masses called hamartomas, which can occur in any organ. But, people with the syndrome are also at high risk of developing a slew of cancerous growths—most commonly cancers of the breast, thyroid, and uterus—over their lifetime. That’s why people diagnosed with the condition are advised to undergo intensive cancer screenings, including annual ultrasounds of the thyroid starting at age 7 and annual mammograms and MRIs (magnetic resonance imaging) starting at age 30 at the latest.

After a series of tumors, woman’s odd-looking tongue explains everything Read More »

RFK Jr. announces 8 appointees to CDC vaccine panel—they’re not good

CDC, health, Robert F Kenned Jr., robert malone, vaccines / Shannon Garcia / June 12, 2025

Anti-vaccine advocate and current Health Secretary Robert F. Kennedy Jr. took to social media Wednesday to announce the names of eight people he is appointing to a critical federal vaccine advisory committee—which is currently empty after Kennedy abruptly fired all 17 previous members Monday.

In the past, the vetting process for appointing new members to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) could take years. But Kennedy has taken just two days.

The panel, typically stocked with vaccine, infectious disease, and public health experts, carefully and publicly reviews, analyzes, and debates vaccine data and offers recommendations to the CDC via votes. The CDC typically adopts the recommendations, which set clinical practices nationwide and determine insurance coverage for vaccinations.

Yesterday, Kennedy pledged that none of the new ACIP members would be “ideological anti-vaxxers.” However, the list of today’s appointees includes Robert Malone, who falsely claims to have invented mRNA vaccines and has spent the past several years spreading misinformation and conspiracy theories about them.

Speaking at an anti-vaccine rally in 2022, Malone spread dangerous falsehoods about mRNA COVID-19 vaccines: “These genetic vaccines can damage your children. They may damage their brains, their heart, their immune system and their ability to have children in the future. Many of these damages cannot be repaired.”

Troubling list

Malone aligned with the anti-vaccine crowd during the pandemic and has become a mainstay in conspiratorial circles and an ally to Kennedy. He has claimed that vaccines cause a “form of AIDS,” amid other nonsense. He has also meddled with responses to the measles outbreak that erupted in West Texas in January. In April, Malone was the first to publicize news that a second child had died from the highly infectious and serious infection, but he did so to falsely claim that measles wasn’t the cause and spread other dangerous misinformation.

RFK Jr. announces 8 appointees to CDC vaccine panel—they’re not good Read More »